S&P 500 Financials Sector SEC Filings — May 18, 2026

18-05-2026

Coca-Cola Europacific Partners plc issued a letter urging shareholders to vote FOR Resolutions 7, 9, and 25 at the May 28, 2026 AGM, despite recommendations against from ISS (on all three) and a "RED" designation from IVIS on Resolution 25. The company argues that the buyback-related waiver (Resolution 25) is necessary to execute its €1bn share buyback programme, and that non-independent directors on the Remuneration Committee (Manolo Arroyo and José Ignacio Comenge) are appropriate given their roles as shareholder representatives and no conflicts. The board emphasizes that Glass Lewis recommends FOR all resolutions and that Olive's maximum potential ownership would be capped at 41.4% with further increases subject to Takeover Code safeguards.

• · Olive has owned in excess of 34% of CCEP since its formation in 2016, and its percentage holding has only modestly increased since then.
• · ISS has recommended voting AGAINST Resolution 25 every year for the past ten years, and its policy has not been updated to reflect the PLSA's 2020 change on Rule 9 waivers.
• · If CCEP repurchases all shares under the current buyback programme (at prevailing price), it would acquire substantially less than 10% of the company's share capital.
• · Glass Lewis recommends voting FOR all resolutions, while IVIS gave a RED designation to Resolution 25 but acknowledged it is a matter for shareholder judgment.
• · The Panel on Takeovers and Mergers has already reviewed and agreed to waive Rule 9, subject to Independent Shareholders' approval via Resolution 25.
• · Mr. Arroyo and Mr. Comenge are not independent directors, but the Remuneration Committee already comprises a majority of INEDs (60% independent).
• · The company states that a vote AGAINST Resolution 25 would effectively block Resolutions 29 and 30 (authority to purchase own shares) and prevent the buyback execution.

18-05-2026

LiveRamp Holdings, Inc. entered into a definitive merger agreement to be acquired by a subsidiary of Publicis Groupe S.A. for $38.50 per share in cash, representing a significant premium. The board unanimously approved the transaction, which is subject to stockholder and regulatory approvals, including CFIUS, with an outside date of May 16, 2027. Concurrently, the company issued financial results for Q4 and fiscal year ended March 31, 2026, but canceled its earnings conference call due to the merger announcement.

• · Merger consideration is $38.50 per share in cash, no stock component.
• · Termination fee of $32,350,000 payable by either party under specified circumstances (Superior Proposal or regulatory failure).
• · Outside date for closing is May 16, 2027, with automatic 3-month extension if only regulatory conditions remain.
• · Equity awards: Options, restricted stock, RSUs, and PSUs convert into restricted cash awards with vesting tied to qualifying terminations within 24 months post-merger.
• · PSU awards: FY25 grants convert at 128% of target; FY26 grants at 139% of target; post-2025 grants at target level.
• · Company canceled its scheduled Q4 FY2026 earnings conference call due to the merger announcement.
• · Merger requires stockholder approval, HSR, non-U.S. antitrust, and CFIUS approvals.
• · Board unanimously approved and recommends stockholders to vote in favor.

18-05-2026

Artificial Intelligence Technology Solutions Inc. (AITX) announced via an 8-K filed on May 18, 2026, that its subsidiary RAD is launching SCANNA, a product designed to unlock smarter security from existing cameras. The announcement was made through a press release attached as Exhibit 99.1. No financial details were provided in this filing.

• · The press release is attached as Exhibit 99.1 to the Form 8-K.
• · The filing was made under Item 8.01 (Other Events) and Item 9.01 (Exhibits).

18-05-2026

Toyota Motor Credit Corporation filed an 8-K on May 18, 2026, furnishing an investor presentation under Regulation FD (Exhibit 99.1). The filing does not contain any financial results or material operational updates; it serves solely to disclose the availability of the presentation to investors.

18-05-2026

Greenland Energy Company filed an 8-K furnishing an updated investor presentation and a press release on May 18, 2026, under Regulation FD. The presentation covers the company's Jameson Land Basin opportunity in East Greenland, its earn-in rights through funded drilling milestones, and the planned OPW-1 and OPW-6 drilling program. The filing includes extensive forward-looking statements and risk factors but contains no specific financial figures or period-over-period comparisons.

• · The investor presentation includes references to prospective recoverable resources, exploration targets, estimated drilling costs, and mobilization activities.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new accounting standards.
• · The filing lists significant risk factors including exploration and geological risks, operational risks in Arctic conditions, regulatory and political risks, and financial and capital risks including going-concern uncertainty.

18-05-2026

Chiba Bank and Chiba Kogyo Bank have agreed on a 1:1 share transfer ratio for their management consolidation via a joint share transfer, forming Chiba Financial Group effective April 1, 2027. The consolidation targets FY2028 consolidated ROE of ~11%, profit attributable to owners of parent of ¥140B or more, and OHR around 40%. While Chiba Kogyo Bank has higher net assets per share (¥2,498 vs ¥1,781) and EPS forecast (¥135.48 vs ¥127.97), it pays a much lower dividend (¥10 vs ¥52), and its stock price has historically shown volatility due to speculation and a prior large shareholder stake. The 1:1 ratio falls within all valuation ranges provided by third-party appraisers.

• · Chiba Bank acquired 19.9% of Chiba Kogyo Bank shares from Ariake Capital on March 28, 2025
• · A memorandum of understanding was announced on September 29, 2025
• · The share transfer ratio of 1:1 was agreed after repeated negotiations, and falls within all three valuation ranges from both third-party appraisers (Mitsubishi UFJ Morgan Stanley Securities and Mizuho Securities)
• · Future elimination of outward preferred dividend flows through acquisition and cancellation of Chiba Kogyo Bank preferred shares is a positive factor for Chiba FG common shareholders
• · Target Tier 1 common equity capital ratio (Basel III full implementation finalization basis, excluding valuation differences on securities) of 10.5–11.5% for FY2028
• · Chiba Kogyo Bank's stock price had been volatile due to speculative reporting and the holding period by Ariake Capital, but such influences have diminished over time

18-05-2026

Irenic Capital Management LP filed its 13F-HR for the quarter ended March 31, 2026, disclosing a $1.54B portfolio across 47 holdings. The largest single position was a put option on iShares Russell 2000 ETF ($323.9M), followed by common stock in Snap Inc. ($138M) and Integer Holdings Corp. ($111.2M), indicating a concentrated, event-driven strategy with notable hedging through derivatives.

• · Total portfolio value of $1.54B as of March 31, 2026.
• · 47 holdings with 4 option positions (2 puts, 2 calls) and 2 convertible note positions.
• · Largest single holding is a put on iShares Russell 2000 ETF ($323.9M) – representing ~21% of portfolio.
• · Second-largest holding is Snap Inc. common stock ($138M), followed by Integer Holdings ($111.2M).
• · Irenic holds call options on First Solar ($42.5M) and Snap Inc. ($26.5M), and a put on Invesco QQQ ($37.3M).
• · The firm has positions in three SPACs: Highview Merger Corp., General Purpose Acquisition Corp., and Safeguard Acquisition Corp.
• · Convertible notes held: Bandwidth Inc. 0.5% due 2026 ($37.6M) and Par Technology Corp. 1.0% ($17.3M).

18-05-2026

18-05-2026

Perma-Fix Environmental Services announced an underwritten public offering of common stock to fund capacity upgrades at its Northwest Richland facility, continued development of its patent-pending Perma-FAS technology for PFAS destruction, and general corporate purposes. Craig-Hallum is acting as sole managing underwriter. The offering is subject to market conditions, with no assurance of completion or final terms.

• · The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283555) declared effective on December 12, 2024.
• · The preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on the SEC's website or from Craig-Hallum.

18-05-2026

The filing is an 8-K reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), indicating that CoreCivic held its annual meeting and/or special shareholder meeting on or around May 18, 2026, and voted on standard proposals. No specific vote results, financial metrics, or forward-looking guidance are provided in the summary, making it purely informational with no directional bias.

18-05-2026

Publicis Groupe SA filed an additional definitive proxy statement (DEFA14A) with the SEC on May 18, 2026, in connection with a proposed transaction with LiveRamp Holdings, Inc. The filing contains cautionary statements regarding forward-looking information and directs investors to review LiveRamp's proxy statement for full details. No financial terms or quantitative data are disclosed in this filing.

18-05-2026

18-05-2026

Outlook Therapeutics reported Q2 FY2026 GAAP net loss of $4.5M, a significant improvement from $46.4M in the prior year period, and posted first product revenue of $0.1M from LYTENAVA sales in Europe. However, adjusted net loss widened to $14.1M from $12.4M, unit sales of LYTENAVA declined ~10% sequentially, and the company holds only $7.7M in cash, underscoring ongoing commercial and regulatory challenges despite completing an FDA dispute resolution meeting for ONS-5010.

• · FDA formal decision on ONS-5010 expected in May 2026
• · Switzerland launch targeted for 2027, subject to Marketing Authorization
• · Cost reduction steps implemented in Europe to improve margins
• · Convertible promissory note restructured in March 2026 to extend maturity to December 2026
• · Non-convertible promissory note entered to reduce outstanding convertible note balance
• · Cash of $7.7M as of March 31, 2026 does not include $4.2M from April 2026 offering

18-05-2026

Coeur Mining, Inc. provided an update on its $750 million share repurchase program, reporting total repurchases of 3,989,969 shares at an average price of $17.46 per share, for approximately $69.7 million as of May 15, 2026. Of these, approximately $60.0 million in repurchases (3,175,840 shares at $18.91 per share) were executed in May 2026. The company retains $680.3 million in remaining authorization under the Plan.

• · Repurchases were executed through opportunistic open-market purchases under a 10b5-1 plan and a 10b-18 agreement with BMO Capital Markets Corp.
• · Average repurchase price for total shares: $17.46; for May 2026 shares: $18.91.

18-05-2026

QXO, Inc. filed an 8-K to provide audited and unaudited consolidated financial statements of Kodiak Building Partners and TopBuild Corp., along with unaudited pro forma combined financial statements for QXO, QXO Building Products (Beacon), Kodiak, and TopBuild, in connection with the pending TopBuild acquisition and prior acquisitions. The filing is procedural and does not disclose specific financial figures.

• · Kodiak audited financials for year ended December 31, 2025, and unaudited for three months ended March 31, 2026 and 2025.
• · TopBuild audited financials for years ended December 31, 2025, 2024, and 2023, and unaudited for three months ended March 31, 2026 and 2025.
• · Unaudited pro forma combined financial statements for QXO, QXO Building Products, Kodiak, and TopBuild for three months ended March 31, 2026 and year ended December 31, 2025.
• · Consents of KPMG LLP (Kodiak's auditor) and PricewaterhouseCoopers LLP (TopBuild's auditor) were filed as exhibits.

18-05-2026

Holley Inc. announced the appointment of Sarah Apple as Senior Vice President, General Counsel and Secretary, effective May 15, 2026, succeeding Carly Kennedy who is departing. Ms. Apple receives a $25,000 signing bonus, an annual base salary of $350,000, a target bonus of 50% of base salary (max 100%), and annual equity awards valued at 75% of base salary. The appointment is part of routine executive succession and compensation arrangements.

• · Ms. Apple joined Holley on April 27, 2026 as a senior advisor to the CEO before the appointment.
• · The employment agreement includes relocation expense reimbursement for her move to Nashville.
• · The signing bonus is subject to repayment if Ms. Apple voluntarily terminates employment without good reason within one year.
• · Severance: if terminated without cause or for good reason, she receives continued base salary for six months (or twelve months if termination occurs within a change-in-control period) plus a pro-rated annual bonus.
• · The equity award for 2026 will be pro-rated based on days employed in 2026.
• · Base salary is subject to annual review and may be increased but not decreased.
• · The press release (Exhibit 99.1) and employment agreement (Exhibit 99.2) are furnished with the 8-K.
• · The information under Item 7.01 is furnished, not filed, for SEC purposes.

18-05-2026

Banzai International, Inc. filed an 8-K/A on May 18, 2026, reporting a Floor Price Amendment (May 15, 2026) to its loan agreement with CP BF Lending. The floor price for converting the outstanding convertible note was reduced from $50.00 to $4.50 per share (post-1-for-20 reverse stock split), while the conversion price remains 95% of the prior trading day's closing price subject to that floor. As of May 14, 2026, the outstanding note balance was $5,361,910, reflecting ongoing dilution risk for existing shareholders.

• · The Floor Price Amendment reduces the conversion floor from $50.00 to $4.50 (post-split), with conversion price at 95% of prior day's closing price subject to floor.
• · CP BF agreed to use commercially reasonable efforts to partially convert the note, with daily volume limit of 5% of aggregate daily trading volume (waivable by company).
• · A Suspension Period applies after the company pays at least $2M of the note's balance, suspending prepayment of proceeds from securities sales until 60 days or $10M gross proceeds received.
• · As of May 14, 2026, the outstanding note balance was $5,361,910, down from $10,758,774.75 at issuance.
• · Company failure to comply with Floor Price Amendment constitutes an Event of Default.

18-05-2026

Faraday Future announced $25M in new convertible note financing, bringing total financing to $70M over two months (including $45M from April), sufficient to support Phase 1 of its EAI robotics strategy by end of 2026. The company raised its full-year shipment target to 1,500 units and declared a shift from liquidity-driven to capital-structure-driven financing. However, only $12.5M is immediately available to the operating account; the remainder is in controlled accounts subject to conditions, and the company continues to face significant risks including insufficient share capital and Nasdaq compliance requirements.

• · SEC investigation concluded with no penalties.
• · Founding team has fully returned to the company.
• · The $25M convertible notes are unregistered and subject to trading restrictions.
• · Of the $25M, $12.5M is directly in the operating account; the remaining $12.5M is in controlled accounts with conditions for release.
• · The full strategic plan (upgraded from Ten-Punch Combo to Five Key Transformations) will be unveiled in YT's Investor Weekly Report on Sunday.
• · Key application scenarios: education, security inspection, reception and guided tours, performance, and university research.
• · Company expects to move EAI Vehicle business away from high-cost short-term funding toward operating cash flow, industry partnerships, and long-term capital.

18-05-2026

Predictive Oncology Inc. filed an 8-K on May 18, 2026, reporting Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a mandatory disclosure of quarterly financial results. However, the filing summary provided does not include any specific financial metrics, performance changes, or forward-looking guidance, preventing a detailed assessment of the company's operational trends or material events.

18-05-2026

Ziff Davis, Inc. announced its participation in the J.P. Morgan 54th Annual Global Technology, Media and Communications Conference on May 18, 2026. The presentation will be webcast. No financial or operational details were disclosed in this filing.

18-05-2026

DynaResource, Inc. filed an 8-K on May 15, 2026, announcing the issuance of a press release regarding its financial results for the first quarter ended March 31, 2026 at the San Jose de Gracia Mine. The press release is attached as Exhibit 99.1. No specific financial figures are disclosed in the 8-K filing itself.

• · Filing includes Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• · Press release is incorporated by reference and not deemed filed under Section 18 of the Exchange Act.

18-05-2026

Estrella Immunopharma reported a net loss of $2.29M for Q1 2026, an 8.9% increase from $2.10M in Q1 2025, driven largely by a 28.5% surge in G&A expenses. However, the company improved its stockholders' deficit from ($10.37M) to ($5.27M) through a $7.24M net registered direct offering and reduced total liabilities by $4.62M, primarily by paying down $4.13M in related party accrued liabilities. Cash increased 39% to $1.93M, but operating cash burn widened dramatically to $6.70M from $0.47M year-over-year, signaling heavy near-term cash consumption.

• · R&D expenses were approximately 61% of total operating expenses in Q1 2026, with $1.375M from related party (same as prior year).
• · G&A expenses increased 28.5% YoY to $891,789, partly due to stock-based compensation of $146,714 in Q1 2026 vs $159,095 in Q1 2025.
• · The company issued 4,063,290 shares of common stock, prefunded warrants, and common stock warrants in a registered direct offering, generating gross proceeds of $7,999,988 but incurring $758,882 in transaction costs.
• · Warrants outstanding surged from 2,214,993 to 10,178,928, with 8,594,935 new warrants granted at a weighted average exercise price of $1.23 (down from $11.50).
• · Aggregate intrinsic value of stock options fell from $2.682M to $0.882M, indicating a significant drop in the company's stock price.
• · Net cash used in operating activities was $6.70M, largely due to a $4.125M payment of related party accrued liabilities.
• · The company had no revenue and remains in the development stage with an accumulated deficit of $39.28M.

18-05-2026

18-05-2026

OLB Group reported a 28.6% decline in total revenue to $1.66M for Q1 2026 compared to $2.32M in Q1 2025, driven by sharp drops in transaction fees (−$540,506) and bitcoin mining revenue (−$37,262). Net loss improved slightly from $1.09M to $1.08M, but operating loss widened to $1.27M from $0.85M. However, cash surged from $15,777 to $2.33M and stockholders' equity nearly doubled to $8.10M, primarily due to $2.62M in prefunded warrant sales and $1.10M in common stock issuances.

• · Accounts payable decreased from $4.46M to $3.72M, partly due to $437K in common stock issued for settlement.
• · Net cash used in operations increased sharply from $156K to $1.34M, reflecting worsening operating cash flows.
• · The company sold 2,166,666 common shares for $1.10M and issued prefunded warrants for $2.62M.
• · Accumulated deficit widened from $74.45M to $75.53M.
• · Weighted average shares outstanding surged from 2.36M to 12.89M, diluting EPS from ($0.47) to ($0.08).

18-05-2026

iSpecimen Inc. reported a sharp 85.2% decline in revenue to $156,009 for Q1 2026 compared to $1,057,510 in Q1 2025, driven by a 86.2% drop in specimen revenue. Net loss widened 37.2% to $2,275,221 from $1,658,396, and cash used in operations nearly tripled to $3,361,846. However, the company reduced operating expenses slightly (flat at ~$2.69M) and benefited from a $261,525 gain on debt settlement, while net loss per share improved from ($28.55) to ($6.66) due to a 5.3x increase in weighted average shares outstanding.

• · Gain on debt settlement of $261,525 in Q1 2026 (none in Q1 2025).
• · Bad debt expense dropped sharply from $111,041 to $368 year-over-year.
• · Sales and marketing expense surged 344.2% to $1,542,297, while technology expense fell 54.6% to $247,549.
• · Total operating expenses remained virtually flat at $2,694,412 vs $2,695,899.
• · The company converted 3,830 shares of Series C convertible preferred stock into 497,280 common shares during Q1 2026.
• · Cash used in investing activities was $700,000 for internally developed software (none in prior year).
• · Accumulated deficit grew to $84,625,370 from $82,350,149.
• · Net loss per share improved from ($28.55) to ($6.66) due to significant share dilution (weighted average shares increased from 58,078 to 341,377).
• · Accounts receivable increased to $132,848 from $48,298, while accounts payable decreased to $4,707,393 from $5,362,604.

18-05-2026

18-05-2026

IMA Tech reported Q3 FY2026 revenues of $0, down from $27,274 in the prior year quarter, and a net loss of $14,433 compared to net income of $1,330. For the nine months, revenues increased 67% to $70,126 but net loss widened to $37,232. Cash declined to $397 from $4,500 at year-end, and stockholders' deficit increased to $(82,873). However, operating cash flow improved significantly to $(24,823) from $(77,885), and general & administrative expenses were cut to $201 in Q3 from $11,712.

• · 2,500,000 common shares were cancelled during the nine months ended January 31, 2026, reducing outstanding shares from 5,109,878 to 2,609,878.
• · Loan from related parties increased to $273,518 as of January 31, 2026 from $252,798 at April 30, 2025.
• · Accumulated deficit grew to $(120,169) from $(82,937) at year-end.
• · Amortization expense remained constant at $14,232 per quarter and $42,695 for each nine-month period.
• · No proceeds from sale of common stock in the current nine months versus $28,647 in the prior period.
• · Prepaid expenses increased to $26,135 from $4,900, a significant rise.

18-05-2026

Presidio Property Trust reported a net loss of $129,632 for Q1 2026, compared to net income of $1.7 million in Q1 2025, driven by lower revenues and higher interest expenses. Total revenues decreased 7.3% to $3.8 million from $4.1 million, primarily due to the sale of Dakota Center. However, rental operating costs as a percentage of revenue improved to 35% from 39%, and the company reduced mortgage debt by $12 million. FFO worsened to ($2.1 million) from ($1.2 million), and Core FFO declined to ($1.9 million) from ($1.0 million). Management expects future interest expenses to decrease and is actively reducing G&A through headcount reductions and a voluntary 5% CEO salary cut.

• · Non-cash impairment charges surged from $26,943 in Q1 2025 to $524,373 in Q1 2026, with approximately $0.4 million related to Shea Center II.
• · Interest expense increased 40% YoY to $2.1 million, including $0.7 million one-time default interest on Dakota Center loan and $0.1 million default interest on Shea Center II loan.
• · Subsequent to quarter end, on April 24, 2026, the company amended its agreement with Origin Bank to decrease the floor interest rate by 1.5 percentage points and requires maintaining $200,000 in liquid assets quarterly.
• · No model homes or commercial properties were acquired during Q1 2026.
• · Segmental breakdown for Q1 2026: Retail segment NOI $88,742, Office/Industrial NOI $1,122,543, Model Homes adjusted NOI $973,004, Corporate and Other NOI $140,527.
• · CEO voluntarily reduced annual salary by 5% starting April 2026, and the Board approved reduction by one director starting June 2026 to further reduce G&A.
• · Mortgage notes payable decreased by $12 million (12.7%) from $94.4M to $82.4M year-over-year.

18-05-2026

GMR Solutions Inc. entered into a Tax Receivable Agreement (TRA) on May 14, 2026, with KKR GMR Consolidated Aggregator LLC and other parties, effective upon the IPO closing date. The TRA provides for payments to TRA parties based on realized tax benefits from tax attributes and imputed interest, with payment mechanisms, subordination, and change-of-control provisions. No specific monetary amounts or financial impacts are disclosed in the filing excerpt.

• · The TRA defines 'Change of Control' events (e.g., acquisition of >50% voting power, merger, liquidation) that can trigger accelerated payment obligations.
• · The agreement includes a subordination clause (Article V) prioritizing payments under the TRA over certain other obligations.
• · Disputes under the TRA are to be resolved through an expert determination process (Section 7.9) or litigation in Delaware.
• · The TRA contains confidentiality provisions and a TRA Party Representative (KKR GMR Consolidated Aggregator LLC) to act on behalf of all TRA parties.

18-05-2026

Brand Engagement Network Inc. entered into a definitive Reseller Agreement with Accelevate Solutions on May 14, 2026, granting its subsidiary SKYE AI USA, LLC exclusive rights to the African continent for an initial five-year term, subject to annual renewal based on minimum revenue thresholds. The licensor will receive 35% of gross revenue (excluding hardware) from sales. While this expands the company's footprint in Africa, the revenue-sharing obligation and performance-based renewal introduce future financial commitments and uncertainties.

• · The agreement includes a joint Pricing Committee and standard indemnification and confidentiality provisions.
• · Exclusive rights are subject to annual renewal based on minimum revenue thresholds for subsequent consecutive years.
• · The Company previously disclosed a letter agreement with Accelevate on April 22, 2026, which led to this definitive agreement.
• · The Company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

18-05-2026

Bitcoin Depot Inc. filed an 8-K on May 18, 2026, reporting multiple material events including a bankruptcy or receivership (Item 1.03), triggering events that accelerate direct financial obligations (Item 2.04), and departure of directors or officers (Item 5.02). The filing indicates a severe financial distress leading to bankruptcy proceedings, but specific financial details, dollar amounts, and names are not disclosed in the provided summary.

• · Filing includes multiple 8-K items (1.03, 2.04, 5.02, 7.01, 9.01) indicating a comprehensive material event.
• · Exact dollar amounts, share counts, and specific executive names are NOT_DISCLOSED in the provided summary.
• · Sector not specified; Bitcoin Depot Inc. is a Bitcoin ATM operator (known from public information, but not in filing).

18-05-2026

18-05-2026

Flux Power Holdings, Inc. entered into a committed equity facility with Roth Principal Investments, LLC, allowing the company to sell up to $40,000,000 of common stock at its sole discretion over a 36-month period. The agreement includes multiple purchase mechanisms (Market Open, Intraday, Pre-Market, Post-Market) and conditions such as a minimum stock price threshold of $0.50 per share. This facility provides potential capital but may lead to dilution for existing shareholders.

• · The per share purchase price for all purchase types is calculated at a fixed 3.0% discount to the applicable VWAP.
• · The registration rights agreement covers up to 38,461,538 shares of common stock.
• · The facility includes a threshold price of $0.50 per share, below which no purchases can be initiated on that trading day.
• · The company may also conduct Intraday Purchases after 10:00 a.m. and before 2:00 p.m. New York City time on qualifying trading days.
• · Pre-Market Purchases are limited to a maximum of 1,000,000 shares and up to 20% of trading volume, with notices delivered between 7:00 a.m. and 8:30 a.m. New York City time.
• · The company has no obligation to sell any shares under the agreement.

18-05-2026

Wyndham Hotels & Resorts CEO Geoff Ballotti disclosed his diagnosis of Multiple Myeloma, a treatable form of bone cancer, which was caught early. He stated his prognosis is favorable and that he will continue working largely as usual while reducing travel, with the full support of the Board. The company reaffirmed its strong start to the year and confidence in delivering value to stakeholders.

• · Geoff Ballotti has been with Wyndham for nearly 20 years.
• · His diagnosis followed two months of chest and back pain initially attributed to an exercise injury.
• · Treatment has begun at Beth Israel/Dana-Farber in Boston, one of the world's leading cancer centers.
• · The Board was notified last week and supports the CEO's continued engagement with reduced travel.

18-05-2026

Yimutian Inc. (YMT) filed an amendment (20-F/A) to its annual report on May 18, 2026, containing boilerplate updates to its memorandum and articles of association regarding share transfer procedures, board authority to issue preferred shares without shareholder vote, and the ability to register by continuation in another jurisdiction. The filing provides no financial data, operational metrics, or material business developments.

18-05-2026

Column Group LLC filed its quarterly Form 13F-HR for the period ending March 31, 2026, disclosing equity holdings in three biotech companies: Oric Pharmaceuticals ($44.86M), Revolution Medicines ($4,474), and Surrozen ($55.84M). The portfolio is concentrated with the largest position in Surrozen, while the Revolution Medicines stake is negligible at only 46 shares.

• · The Revolution Medicines position is de minimis at only 46 shares, representing a market value of $4,474.
• · The filing was signed by CFO James Evangelista on May 15, 2026.
• · No period-over-period comparisons are available from this single filing, as this is a single-quarter snapshot.

18-05-2026

18-05-2026

18-05-2026

Context Therapeutics entered into an amendment to its exclusive license agreement with BioAtla for CT-202, its Nectin-4 x CD3 T cell engager. The amendment removes all future milestone and royalty obligations in exchange for a $4.5 million upfront payment and a second $2.0 million payment due by August 1, 2026, granting Context a fully paid-up, non-terminable license. The company expects to initiate a Phase 1 clinical trial for CT-202 in the third quarter of 2026.

• · CT-202 targets Nectin-4, a cell surface protein overexpressed in bladder, colorectal, lung, and breast cancers.
• · CT-202 is a pH-dependent TCE designed for preferential activity within the tumor microenvironment.
• · The clinical trial identifier for the Phase 1 study is NCT07545122.
• · Context's pipeline includes CTIM-76 (Claudin 6 x CD3 TCE) and CT-95 (Mesothelin x CD3 TCE).

18-05-2026

SkyBridge Capital II, LLC filed its 13F-HR for the quarter ended March 31, 2026, disclosing a portfolio valued at $13.13 billion. The portfolio is heavily concentrated in cryptocurrency-related assets, with Strategy Inc (formerly MicroStrategy) and iShares Bitcoin Trust comprising approximately 97% of total holdings. Other positions include Chime Financial, Circle Internet Group, and Klarna Group.

• · The portfolio is heavily concentrated: Strategy Inc and iShares Bitcoin Trust together represent about $12.8 billion, or 97% of total holdings.
• · No options, warrants, or derivative instruments were reported; all holdings are common shares or ETF shares.
• · The filing does not provide prior period comparisons, so no quarter-over-quarter changes are available.

18-05-2026

Castellum, Inc. filed an 8-K on May 18, 2026, disclosing a press release and presentation regarding the 2026 Annual Stockholders Meeting. The filing contains no financial results or material operational updates; it is purely procedural for meeting logistics.

18-05-2026

GoPro, Inc. announced a complete legal victory in its patent infringement case with Contour IP Holding LLC. The court granted GoPro's motion for judgment as a matter of law, invalidating the sole remaining patent claim as obvious, vacating the $8.2 million damages award, and denying all of CIPH's post-trial motions. As a result, GoPro has no liability from the case, though the ruling is subject to appeal to the Federal Circuit.

• · Jury verdict on October 10, 2025 found no infringement for products commercially launched 2020-2024 and invalidated one of two asserted patents' only claim, but found one claim valid and infringed for legacy products, awarding $8.2M.
• · On May 14, 2026, the Court granted GoPro's motion for judgment as a matter of law, finding claim 11 of U.S. Patent No. 8,890,954 invalid as obvious.
• · All asserted claims of both patents have been found invalid; the $8.2M award was vacated in its entirety.
• · CIPH's motions for judgment as a matter of law and for a new trial were denied.
• · The Court's ruling is subject to appeal to the U.S. Court of Appeals for the Federal Circuit.

18-05-2026

lululemon athletica inc. filed its definitive proxy statement for the 2026 annual meeting, highlighting the appointment of Heidi O'Neill as the next chief executive officer (effective September 8, 2026) following Calvin McDonald's departure in December 2025. The board also appointed Martha Morfitt as executive chair to support interim co-CEOs during the transition. While 83% of votes cast supported the say-on-pay proposal at the 2025 meeting, the compensation committee made no direct changes to the program in response to the vote, maintaining existing design.

• · Non-employee directors receive an annual restricted stock award with a fair value of approximately $160,000, subject to one-year vesting.
• · The board enforces limits on outside activities: current CEO directors may serve on no more than two additional public company boards; non-executive directors on no more than four.
• · The audit committee oversees cybersecurity risks via a dedicated subcommittee that meets quarterly with management.
• · The company's enterprise risk management program is led by senior leaders and coordinated by cross-functional teams; results are shared regularly with the board.
• · The next advisory vote on the frequency of say-on-pay will occur no later than the 2029 annual meeting.

18-05-2026

Gossamer Bio announced an exchange offer to swap its existing 5.00% Convertible Senior Notes due 2027 for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock (or prefunded warrants), and purchase warrants. The offer requires at least 98% participation and includes a consent solicitation to eliminate restrictive covenants. Concurrently, the company will seek stockholder approval to increase authorized shares from 700M to 4B and approve a reverse stock split (1-for-10 to 1-for-150), reflecting significant financial restructuring and potential dilution.

• · New notes have springing maturity of March 2, 2027 if more than $4.0M of existing notes remain outstanding.
• · Conversion rate for new notes is based on a 10% premium to Reference Price, with Reference Price floored at $0.17 and capped at $0.34.
• · Purchase warrants exercisable from December 3, 2026 to June 3, 2031 with exercise price at greater of $0.34 and 125% of Reference Price.
• · Liquidity covenant starts at $40M, reduces to $20M after $100M equity raise, to $10M after FDA acceptance of NDA filing by Dec 1, 2026, and to $0 after total $150M equity raise.
• · Early tender date: June 1, 2026; Expiration deadline: June 16, 2026; Early settlement expected June 3, 2026; Final settlement expected June 18, 2026.
• · Proposed reverse stock split range: 1-for-10 to 1-for-150, with exact ratio determined by Board later.
• · Stockholder approval needed to allow physical share settlement of new notes and warrants; prior to that, only cash settlement allowed.
• · Existing note holders who tender after early tender date but before expiration will not receive purchase warrants.

18-05-2026

Artivion completed its acquisition of Endospan Ltd., an Israeli developer of aortic instability treatments including the Nexus™ stent graft system. The all-cash transaction had a base purchase price of $175.0 million, with a net cash payment of approximately $131.3 million after offsetting existing loans. Additional contingent consideration of up to $200.0 million may be payable based on Nexus product performance approximately two years post-closing.

• · The acquisition was executed via exercise of an option originally granted under a Securities Purchase Option Agreement dated September 11, 2019, as amended on July 1, 2024 and January 9, 2026.
• · Payment was made by CryoLife Asia Pacific Pte. Ltd., a wholly owned subsidiary of Artivion.
• · The net purchase price after offsetting loans under the Amended and Restated Loan Agreement (dated July 1, 2024) was approximately $131.3 million.
• · Escrow accounts of $16.5 million (indemnity) and $1.0 million (adjustment) were established from the purchase price.

18-05-2026

18-05-2026

LanzaTech Global, Inc. entered into a securities purchase agreement to sell 2,000,000 shares of common stock at $10.00 per share in a registered direct offering, generating gross proceeds of $20.0 million. Concurrently, the company amended its existing subscription agreement with LanzaTech Global SPV, LLC, lowering the cash balance threshold for additional share purchases from $40 million to $30 million. Net proceeds from the offering will be used for general corporate purposes.

• · The offering was conducted under an effective shelf registration statement on Form S-3 (File No. 333-279239).
• · Closing of the offering is expected on May 18, 2026.
• · The PIPE subscription amendment also provided that LT Global consented to the offering in connection with its consent rights over future financings.
• · The Company has until May 13, 2027, to require LT Global to purchase up to an additional $20.0 million of shares, subject to the lowered cash requirement of $30 million.